|Assessment process complete
|For the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and taxane, separately or in combination.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full Pharmacoeconomic Assessment Recommended.
|Full pharmacoeconomic assessment commissioned by HSE
|NCPE assessment completed
|NCPE assessment outcome
|Reimbursement Not Recommended.
The NCPE do not recommend reimbursement of trastuzumab emtansine (Kadcyla®) at the submitted price.
The HSE has approved reimbursement following confidential price negotiations.